However, in the non-HPD group, two patients on anti-PD-1 therapy and four patients on anti-PD-1-CTLA-4 therapy had permanent discontinuation, with one patient on anti-PD-1 therapy dying from grade 3 myocarditis. Here, CTLA4 is linked to myocarditis.